Artesunate suppresses Th17 response via inhibiting IRF4-mediated glycolysis and ameliorates Sjogren's syndrome  

作　　者：Fan Xiao Ke Rui Man Han Liyun Zou Enyu Huang Jie Tian Lijun Zhang Quan Jiang Yuzhang Wu Liwei Lu 

机构地区：[1]Department of Pathology and Shenzhen Institute of Research and Innovation,Shenzhen Hospital,The University of Hong Kong [2]Chongqing International Institute for Immunology,Hong Kong,China [3]Department of Laboratory Medicine,Affliated Hospital and,Institute of Medical Immunology,Jiangsu University,Zhenjiang,China [4]Division of Rheumatology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Bejjing,China Institute of Immunology,Army Medical University,Chongqing,China

出　　处：《Signal Transduction and Targeted Therapy》2022年第9期3210-3212,共3页信号转导与靶向治疗（英文）

基　　金：This work was supported by Chongqing International Institute for Immunology(2020YJC10);National Natural Science Foundation of China(82071817,82171771,82004171,81971542);Shenzhen Science and Technology Program(YCYJ20210324114602008);Young Elite Scientist Sponsorship Program by CACM(CACM-2020-QNRC2-05);Hong Kong Research Grants Council(17113319,17103821);RGC Theme-based Research Scheme(TRS)(T12-703/19-R);the Centre for Oncology and Immunology under the Health@InnoHK Initiative funded by the Innovation and Technology Commission,The Government of Hong Kong SAR,China.

摘　　要：Dear Editor,Primary Sjogren's syndrome(pSS)is an autoimmune disease characterized by dry eyes and dry mouth caused by glandular inflammation in salivary glands(SG)and lacrimal glands.Currently,pSS patients are suffering from a lack of effective therapies.Many studies have revealed dysregulated immune responses during pSS development,in which Th17 cells are considered as the key driver in disease initiation and perpetuation.

关 键 词：TH17 SJOGREN INHIBITING 

分 类 号：R285.5[医药卫生—中药学]